Neuraly launches with $36 million Series A to develop neurological disease drug
Nature Medicine mouse study shows once-weekly GLP-1 receptor agonist slowed Parkinson's disease progression.
Germantown
Nature Medicine mouse study shows once-weekly GLP-1 receptor agonist slowed Parkinson's disease progression.